Personalis Net Profit Margin 2018-2025 | PSNL

Personalis net profit margin from 2018 to 2025. Net profit margin can be defined as net Income as a portion of total sales revenue.
Personalis Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2025-03-31 $0.09B $-0.08B -96.55%
2024-12-31 $0.09B $-0.08B -94.19%
2024-09-30 $0.09B $-0.09B -103.37%
2024-06-30 $0.08B $-0.08B -101.23%
2024-03-31 $0.08B $-0.09B -124.00%
2023-12-31 $0.07B $-0.11B -147.30%
2023-09-30 $0.07B $-0.11B -159.15%
2023-06-30 $0.07B $-0.11B -161.76%
2023-03-31 $0.07B $-0.11B -165.22%
2022-12-31 $0.07B $-0.11B -173.85%
2022-09-30 $0.07B $-0.10B -147.83%
2022-06-30 $0.08B $-0.09B -123.68%
2022-03-31 $0.08B $-0.08B -101.25%
2021-12-31 $0.09B $-0.07B -75.58%
2021-09-30 $0.09B $-0.06B -68.24%
2021-06-30 $0.08B $-0.05B -60.24%
2021-03-31 $0.08B $-0.04B -55.00%
2020-12-31 $0.08B $-0.04B -52.56%
2020-09-30 $0.08B $-0.04B -46.05%
2020-06-30 $0.07B $-0.03B -43.84%
2020-03-31 $0.07B $-0.03B -41.43%
2019-12-31 $0.07B $-0.03B -40.00%
2019-06-30 $0.04B $-0.02B -38.10%
2019-03-31 $0.04B $-0.02B -48.57%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.518B $0.085B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.865B 7.10
Dr Reddy's Laboratories (RDY) India $13.298B 24.14
BridgeBio Pharma (BBIO) United States $7.415B 0.00
Bausch Health Cos (BHC) Canada $1.973B 1.42
Supernus Pharmaceuticals (SUPN) United States $1.856B 15.07
Amphastar Pharmaceuticals (AMPH) United States $1.228B 8.24
Taysha Gene Therapies (TSHA) United States $0.573B 0.00
Assembly Biosciences (ASMB) United States $0.130B 0.00
Sol-Gel Technologies (SLGL) Israel $0.019B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00